ACCORDION is a prospective, observational follow-up study of more than 8000 participants who were treated and followed in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial, over 10000 participants. The study was to further elucidate and clarify the long-term effects of intensive control of hyperglycemia, dyslipidemia, high blood pressure as implemented in the ACCORD trial. Here we reported the long-term effect of the three intervention strategies on health related quality of life (HRQOL). Data used to derive three HRQOL measurements (utility index mark 2 (HUI-2), utility index mark 3 (HUI-3) and feeling thermometer (FT) were collected at baseline, 12 months, 36 months, 48 months, and end of the original ACCORD study and at 27 and 57 months in the follow-up study. Linear mixed effects models, controlling for stratification factors and baseline utility score were used to assess the effect of intervention assignment on mean HUI-2, HUI-3 and FT scores. Intensive therapy for glycemia, blood pressure, or lipids had no observed adverse or beneficial effect on HRQOL measures during both trial and follow-up periods (Table, available in the journal Diabetes). These results should be considered in the context of the clinical results of the ACCORD/ACCORDIAN studies, when considering the advantages and limitations of diabetes care strategies.